Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM

Diabetes Care

Volumn 19, Issue 12, 1996, Pages 1357-1363

  Pozzilli, Paolo ^a,b   Browne, Peter D ^b   Kolb, Hubert ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; NICOTINAMIDE;

ADOLESCENT; ADULT; ARTICLE; CELL PROTECTION; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PANCREAS ISLET BETA CELL; SCHOOL CHILD;

EID: 0029963459     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.12.1357     Document Type: Article

References (39)

1. Warburg O, Christian W: Co-ferment problem. Biochimie (Paris) 274:122-125, 1934
2. Yonemura Y, Takishima T, Miwa K, Miyakazi I, Yamamoto H, Okamoto H: Amelioration of diabetes mellitus in partially depancreatized rats by poly (ADP-ribose) synthetase inhibitors. Diabetes 33:401-404, 1984
3. Sandler S, Anderson A: Long term effects of exposure of pancreatic islet to nicotinamide in vitro on DNA synthesis metabolism and B-cell function. Diabetologia 29:199-202, 1986
4. Pipeleers D, van De Winkel M: Pancreatic B cells possess defense mechanisms against cell-specific toxicity. Proc Natl Acad Sci USA 83:5267-5271, 1986
5. Burkart V, Koike T, Brenner HH, Kolb H: Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. Diabetologia 35:1028-1034, 1992
6. Kallmann B, Burkart V, Kroncke KD, Kolb-Bachofen V, Kolb H: Toxicity of chemically generated nitric oxide towards pancreatic islet cell can be prevented by nicotinamide. Life Sci 51:671-678, 1992
7. + depletion. Biochem Biophys Res Commun 199:1270-1277, 1994
8. Cetkovic-Cvrlje M, Sandler S, Eizirik DL: Nicotinamide and dexamethasone inhibit IL-1 induced nitric oxide production by RINm5F cells without decreasing mRNA expression for nitric oxide synthase. Endocrinology 133:1739-1743, 1993
9. Andersen HU, Jorgensen KH, Egeberg J, Mandrup-Poulsen T, Nerup J: Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 43:770-777, 1994
10. Eizirik DL, Sandler S, Welsh N, Bendtzen K, Hellerstrom C: Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines. Autoimmunity 19:193-198, 1994
11. Yamada K, Miyajima E, Nonaka K: Inhibition of cytokine-induced MHC class II but not class I molecule expression on mouse islet cells by nicotinamide and 3-aminobenzamide. Diabetes 39:1125-1130, 1990
12. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S: Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis: an observation in nonobese diabetic (NOD) mice. Diabetes 31:749-753, 1982
13. Bowman MA, Leiter EH, Atkinson MA: Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease (Review). Immunol Today 15:115-119, 1994
14. Elliott RB, Richer CC, Stewart A, Fergusson D, McGregor MA: The use of nicotinamide in the prevention of type 1 diabetes: immunosuppressive and anti-inflammatory drugs. Ann NY Acad Sci 696:333-338, 1993
15. Vague PH, Vialettes B, Lassman-Vague V, Vallo JJ: Nicotinamide may extend remission phase in insulin dependent diabetes. Lancet i:619, 1987
16. Pozzilli P, Visalli N, Ghirlanda G, Manna R, Andreani D: Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. Diabet Med 6:568-572, 1989
17. Vague P, Picq R, Bernal M, Lassmann-Vague V, Vialettes B: Effect of nicotinamide treatment on the residual insulin secretion in Type 1 (insulin dependent) diabetic patients. Diabetologia 32:316-321, 1989
18. Mendola G, Casamitjana R, Gomis R: Effect of nicotinamide therapy upon β-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 32:A160, 1989
19. Gonzalez-Clemente JM, Munoz A, Fernandez-Usac E: Desferrioxamine and nicotinamide in newly diagnosed type 1 diabetic patients: a randomized double blind placebo controlled trial (Abstract). Diabetologia 35:A202, 1992
20. Paskova M, Ikao I, Trozova D, Bono P: Nicotinamide treatment in children with newly diagnosed type 1 diabetes mellitus. Diabetologia 35:A203, 1992
21. Chase HP, Butler-Simon N, Garg S, McDuffie M, Hoops SL, O'Brien D: A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33:114-146, 1990
22. Lewis CM, Canafax DM, Sprafka JM, Barbosa JJ: Double-blind randomized trial of nicotinamide on early onset diabetes. Diabetes Care 15:121-123, 1992
23. Vialettes B, Picq R, du Rostu M, Charbonnel B, Rodier M, Mirouze J, Vexiau P, Passa P, Pahuet M, Elgrably F: A preliminary multicenter study of the treatment of recently diagnosed type 1 diabetes by combination nicotinamide-cyclosporin therapy. Diabet Med 7:731-735, 1990
24. Pozzilli P on behalf of the IMDIAB Study Group: Combination of nicotinamide and steroid versus nicotinamide in recent onset insulin-dependent diabetes (The IMDIAB II Study). Diabetes Care 17:897-900, 1994
25. Pozzilli P on behalf of the IMDIAB Study Group: Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes. Diabet Med 11:98-104, 1994
26. Pozzilli P, Visalli N, Signore A, Baroni MG, Buzzetti R, Cavallo MG, Boccuni ML, Fava D, Gragnoli C, Andreani D, Lucentini L, Matteoli MC, Crino A, Cicconetti CA, Teodonio C, Paci F, Amoretti R, Pisano L, Pennafina MG, Santopadre G, Marozzi G, Multari G, Suppa MA, De Mattia GC, Cassone Faldetta M, Marietti G, Perrone F, Greco AV, Ghirlanda G: Double blind trial of nicotinamide in recent onset insulin dependent diabetes mellitus. Diabetologia 38:848-852, 1995
27. Ilkova H, Gorpe U, Kadioglu P, Ozyazar M, Bagriacik N: Nicotinamide in type 1 diabetes mellitus of recent onset: a double blind, placebo controlled trial (Abstract). Diabetologia 34 (Suppl. 2):A179, 1991
28. Guastamacchia E, Ciampolillo A, Lollino G, Caragiulo L, De Robertis O, Lattanzi V Giorgino R: Effetto della terapia con nicotinamide sull'induzione della durata della remissione clinica in diabetici di tipo 1 all'esordio sottoposti a terapia insulinica ottimizzata mediante microinfusore (Abstract). Il Diabete (Suppl. 1) 4:210, 1992
29. Taboga C, Tonutti L, Noacco C: Residual beta cell activity and insulin requirements in insulin-dependent diabetic patients treated from the beginning with high doses of nicotinamide: a two year follow-up. Recenti Prog Med 85:513-516, 1994
30. Hanafusa T, Miyagawa J, Itoh N, Yamagata K, Otsuka A, Asakawa H, Miyazaki A, Kono N, Tarui S: Nicotmamide treatment for IDDM: three years' experience in Japan. In The 11th International Immunology and Diabetes Workshop. Nagasaki, Japan, 1991, p. A35
31. Staman I, Dinccag N, Karsidag K, Ozer E, Altuntas Y, Yilmaz MT: The effect of nicotinamide in recent onset type 1 diabetes regarding the level of beta cell reserve. Klinik Gelisim 8:3882-3886, 1995
32. Mandrup-Poulsen T, Reimers JI, Andersen HU, Pociot F, Karlsen AE, Bjerre U, Nerup J: Nicotinamide treatment in the prevention of insulin dependent diabetes mellitus. Diab Metab Rev 9:295-309, 1993
33. Pozzilli P, Andreani D: The potential role of nicotinamide in the secondary prevention of IDDM. Diab Metab Rev 9:219-230, 1993
34. Whitehead A, Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10:1665-1677, 1991
35. Kolb H, Dannehl K, Gruneklee D, Zielasek J, Bertrams J, Hubinger A, Gries FA: Prospective analysis of islet cell antibodies in children with type 1 (insulin-dependent) diabetes. Diabetologia 31:189-194, 1988
36. Peig M, Gomis R, Ercilla G, Casamitjana R, Bottazzo GF, Pujol-Borrell R: Correlation between residual β-cell function and islet cell antibodies in newly diagnosed type 1 diabetes: follow-up study. Diabetes 38: 1396-1401, 1989
37. Karjalainen J, Salema P, Ilonen J, Surcel HM, Knip M: A comparison of childhood and adult type 1 diabetes mellitus. N Engl J Med 320:881-886, 1989
38. Pozzilli P, MacLaren NK: Immunotherapy at clinical diagnosis of insulin dependent diabetes: an approach still worth considering. Trends Endocrinol Metab 4:101-105, 1993
39. Gale EAM, Bingley PJ: Can we prevent IDDM? Diabetes Care 4:339-344, 1994